Editorial : Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 14(2023) vom: 19., Seite 1210002 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Girardin, François R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cost-effectiveness |
|---|
| Anmerkungen: |
Date Revised 04.06.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2023.1210002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357633806 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357633806 | ||
| 003 | DE-627 | ||
| 005 | 20231226073023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2023.1210002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357633806 | ||
| 035 | |a (NLM)37261286 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Girardin, François R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Editorial |b Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.06.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a cost-effectiveness | |
| 650 | 4 | |a disinvestment choices | |
| 650 | 4 | |a health technology assessment (HTA) | |
| 650 | 4 | |a patient related outcome | |
| 650 | 4 | |a pharmacoeconomics | |
| 700 | 1 | |a Cohen, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Schwenkglenks, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Durand-Zaleski, Isabelle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 14(2023) vom: 19., Seite 1210002 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:19 |g pages:1210002 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2023.1210002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 19 |h 1210002 | ||